Ask an Expert is a free question-and-answer service about breast cancer and breast health that is available on weekends. If you'd like to ask a question or comment, please visit us again on Saturday or Sunday. In the meantime, please search the existing topics using the search tool at the top of the page. It's quite possible that one of our many existing topics already addresses your question.
If you would like a consultation with a breast specialist at the Johns Hopkins Avon Foundation Breast Center, call 443-778-2778. It is possible to get an appointment for a second opinion within a few days of contacting us.
We hope you find the information helpful!
| Forum | Questions | Ask a Question | |
|---|---|---|---|
 |
LCIS - Lobular Carcinoma In Situ Questions about lobular carcinoma in situ. |
142 |  |
| Asked | Publicly Submitted Question | ||
|---|---|---|---|
| 5/5/2010 | What type of hormonal therapy is recommended for breast cancer prevention? I have taken tamoxifen for 5 years, and am now on Femara just finishing up my 6TH year.What about Reloxifen? My oncologist doesn't seem very concerned and waits for me to make a suggestion as to my preference of which drug to take next. | ||
| Replied | JHU's Breast Center Reply | ||
| 5/5/2010 | tamoxifen for those who have increased risk and have never had breast cancer. for those who have had breast cancer then it depends on menopausal status and type of breast cancer. L | ||
Please note: This service is not intended to provide primary medical advice concerning specific medical care or treatment. Ask an Expert is a free service operated by health care professionals at the Johns Hopkins Avon Foundation Breast Center. Due to the volume of questions and their complexity, there are times when medical oncologists, surgeons, radiation oncologists or oncology nurses are consulted for their input. These individuals volunteer their time for this service and will respond as soon as they are able. Please do not post or send the same question to us in multiple locations or categories.